ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Madrigal Pharmaceuticals, Inc. clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 46 studies whose lead sponsor is Madrigal Pharmaceuticals, Inc. or the company grouped under it. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 16, 2026.

Our grouping of 2 registry names, not the registry’s. See them and correct one ↓

Compare Madrigal Pharmaceuticals with Jiangsu HengRui Medicine and GlaxoSmithKline →

Pipeline: 1 program

Each counted once: 1 with a study Madrigal Pharmaceuticals, Inc. leads registered in the last two years.

  • Phase 4 (approved, new studies)

The 1 program — sign in to see the list, free: with every program, filter by condition or phase and sort by first study or primary completion.

Not counted: 2 approved drugs Madrigal Pharmaceuticals, Inc. gives alongside its own in its studies — dapagliflozin (with resmetirom); pioglitazone (with resmetirom). Our rule: a drug many companies test, in every study Madrigal Pharmaceuticals, Inc. led of it in the last two years beside a drug of its own.

“Registry” is the highest phase of Madrigal Pharmaceuticals, Inc.’s own registered studies; Madrigal Pharmaceuticals, Inc.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Madrigal Pharmaceuticals, Inc.’s studies test, most open studies first — 12 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 2 more

Coming up

4 of Madrigal Pharmaceuticals, Inc.’s studies under way reach primary completion within a year, 2 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. 1D
  3. J’27
  4. F
  5. 1M
  6. A
  7. M
  8. J
  9. J
  10. A
  11. S
  12. O
  13. 2N

Add all 4 to your calendar (.ics) → With an account.

All 46 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now511%
  • Under way, not recruiting37%
  • Completed3270%
  • Stopped early49%Terminated 3 · Suspended 1
  • Status unknown or other24%

Phase

  • Phase 125
  • Phase 216
  • Phase 37
  • Phase 41

Where

  • United States43
  • Canada10
  • Spain6
  • United Kingdom6
  • Belgium5
  • Germany5

Over the years

  1. 07
  2. 08
  3. 409
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 15
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 426

By the year each study started; 10 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Madrigal Pharmaceuticals, Inc.

  • Synta Pharmaceuticals Corp.
    Acquired — became part of Madrigal Pharmaceuticals, Inc., Jul 22, 2016 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    25 studies →
  • Madrigal Pharmaceuticals, Inc.
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    21 studies

Studies

Recruiting first, then most recently updated. Showing 46 of 46.